Wire · opportunities
FDA Approves Zidesamtinib for Pretreated ROS1-Positive NSCLC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 July 2026 · Fusion42 review
FDA approved zidesamtinib (Jideytro), a next-generation ROS1 inhibitor, for metastatic ROS1-positive NSCLC in patients previously treated with kinase inhibitors, two months ahead of schedule. The ARROS-1 trial showed 44% objective response rate with durable responses in heavily pretreated patients, including those with brain metastases and resistance mutations.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you build diagnostics, monitoring tools, or patient support software for ROS1-positive lung cancer, you now have a proven second-line therapy with a 44% response rate—meaning the addressable patient pool just expanded and clinicians need new ways to track resistance mutations and brain metastases. GSK's early approval signals the FDA is fast-tracking precision oncology, which means your regulatory path got shorter and your buyer pool got hungrier.
◆ Coverage
1 source · 23 Jul 2026
◆ Related on Wire
◆ Topics